48
https://pubmed.ncbi.nlm.nih.gov/38094680
The genetic variant rs17171731, associated with atrial fibrillation risk, decreases FAM13B expression, leading to altered ion channel expression and pro-arrhythmogenic changes, suggesting FAM13B as a potential target for patient-specific therapeutics.